Literature DB >> 20850649

Predictive and prognostic value of preoperative symptoms in the surgical treatment of pulmonary aspergilloma.

Dariusz Sagan1, Kazimierz Goździuk, Elzbieta Korobowicz.   

Abstract

BACKGROUND: Surgical resection is widely accepted as the treatment of choice for pulmonary aspergilloma (PA). However, the technique involved ranks among the most challenging in thoracic surgery and remains associated with considerable morbidity and mortality. To improve the outcomes, it is essential to establish clear recommendations for optimal timing of surgery and selection of patients. To facilitate this, we analyzed the impact of preoperative clinical factors on the results of treatment.
METHODS: Medical records of patients treated surgically for PA between 1979 and 2007 were retrospectively reviewed for clinical variables of potential impact on the surgical outcome with emphasis on preoperative symptoms.
RESULTS: Sixty-four patients, including 22 cases of simple aspergilloma and 42 cases of complex aspergilloma were enrolled in the study. Univariable analysis followed by multivariable logistic regression identified weight loss and massive hemoptysis as risk factors for postoperative morbidity [odds ratio (OR) = 8.856, P = 0.006 and OR = 6.9, P = 0.021, respectively]. Ten-year cumulative survival in simple aspergilloma and complex aspergilloma was 88.3% and 70.6%, respectively (P = 0.042). Multivariable analysis by Cox proportional hazard model showed that younger age and lack of massive hemoptysis were independent favorable prognostic factors [hazard ratio (HR) = 1.13, P = 0.0004 and HR = 4.71, P = 0.0319, respectively).
CONCLUSION: Massive hemoptysis is an independent unfavorable predictive and prognostic factor in the surgical treatment of PA. We believe that in operable cases, early surgical resection may be recommended even in asymptomatic patients. This strategy may prevent development of life-threatening symptoms and offers a realistic chance of permanent cure with acceptable mortality and morbidity.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20850649     DOI: 10.1016/j.jss.2010.06.039

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  6 in total

1.  Lung parenchyma surgery in autosomal dominant hyper-IgE syndrome.

Authors:  Alexandra F Freeman; Ellen D Renner; Carolyn Henderson; Anne Langenbeck; Kenneth N Olivier; Amy P Hsu; Beate Hagl; Annette Boos; Joie Davis; Beatriz E Marciano; Lisa Boris; Pamela Welch; Julie Sawalle-Belohradsky; Bernd H Belohradsky; King F Kwong; Steven M Holland
Journal:  J Clin Immunol       Date:  2013-04-13       Impact factor: 8.317

2.  Cavernostomy x resection for pulmonary aspergilloma: a 32-year history.

Authors:  Jorge Ms Cesar; Jose S Resende; Nilson F Amaral; Carla Ms Alves; Alyne F Vilhena; Frederico L Silva
Journal:  J Cardiothorac Surg       Date:  2011-10-05       Impact factor: 1.637

3.  Surgery for localized pulmonary mycotic infections in patients with hematopoietic disorder.

Authors:  Youngkyu Moon; Jae Kil Park; Sook Whan Sung
Journal:  J Cardiothorac Surg       Date:  2015-06-30       Impact factor: 1.637

4.  Clinical Features, Diagnostic Test Performance, and Prognosis in Different Subtypes of Chronic Pulmonary Aspergillosis.

Authors:  Huanhuan Zhong; Yaru Wang; Yu Gu; Yueyan Ni; Yu Wang; Kunlu Shen; Yi Shi; Xin Su
Journal:  Front Med (Lausanne)       Date:  2022-02-11

5.  Factors affecting survival after anatomical lung resection in pulmonary aspergilloma: Our 10-year single institution experience.

Authors:  Celal Buğra Sezen; Cemal Aker; Mustafa Vedat Doğru; Yunus Aksoy; Salih Bilen; Yaşar Sönmezoğlu; Volkan Erdoğu; Levent Cansever; Muzaffer Metin
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-01-28       Impact factor: 0.332

Review 6.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.